| System | Observations (Phase I/II) | |--------|---------------------------| | | No deaths; most AEs ≤ Grade 1. | | Gastro‑intestinal | Mild nausea (≈ 8 %); transient dyspepsia (≈ 5 %). | | Neurologic | No seizures, dizziness, or visual disturbances reported. | | Cardiovascular | No QTc prolongation (> 10 ms) at any dose; BP unchanged. | | Hepatic/renal | Transaminases ≤ 1.5×ULN; creatinine unchanged. | | Immunologic | Slight ↓ in peripheral IL‑6 (statistically significant at 150 mg). No opportunistic infections. | | Special populations | No data yet for elderly > 80 y, hepatic impairment, or pediatrics. |
The presence of JUQ-473 in various online platforms and databases suggests that it may be a significant player in its respective industry. For instance: JUQ-473
The team—Lena, Malik, a robotics engineer named Jace, and a security officer, Rhea—descended through a shaft that cut through centuries of sand. Their boots clanged against the cold, metallic floor, and the faint hum of ancient power lines brushed the back of their throats. | | Cardiovascular | No QTc prolongation (>
